PD
APLS

Point72 (DIFC)’s Apellis Pharmaceuticals APLS Stock Holding History

Point72 (DIFC)’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$330K Buy
+14,591
New +$340K 0.02% 352
2025
Q1 		– Sell
-8,009
Closed -$256K – 1651
2024
Q4 		$256K Buy
+8,009
New +$241K 0.01% 819

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 (DIFC)'s APLS Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Apellis Pharmaceuticals (APLS) in Q3 2025: 14,591 shares worth $330K. The stake represents 0.02% of the portfolio and ranks #352 among its holdings. This is a return to the name: Point72 (DIFC) previously reported a position in APLS as recently as Q4 2024.

Point72 (DIFC) first reported a position in APLS in Q4 2024 and has held it in 2 quarters since. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Point72 (DIFC) held 14,591 shares of Apellis Pharmaceuticals worth $330K as of Q3 2025.
  • Apellis Pharmaceuticals was a new Point72 (DIFC) position in Q3 2025.
  • Apellis Pharmaceuticals made up 0.02% of Point72 (DIFC)'s portfolio in Q3 2025, its #352 holding.
  • Point72 (DIFC) first reported a position in Apellis Pharmaceuticals in Q4 2024 and has held it in 2 quarters since.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.